Value of SPET/CT image fusion in the assessment of neuroendocrine tumours with 111In-pentetreotide scintigraphy by Moreira, AP et al.
Summary.—Objective: The purpose of this study was to
evaluate the impact and clinical value of anatomical-functional
image fusion in the study interpretation and clinical manage-
ment of patients with neuroendocrine tumours (NET) using
somatostatin receptor scintigraphy (SRS) and combined trans-
mission and emission tomography – single-photon emission
tomography/CT (SPET/CT).
Material and methods: Twelve patients (8 female and 4 male;
age range 32-74 y, mean 56 y) with proven or clinically suspect-
ed NET were studied with routine planar SRS and SPET/CT at
2 and 24 hours after injection of 111-222 MBq 111In-Pente-
treotide. Seven patients came for staging/follow-up and 5 pa-
tients for primary tumour localization with staging. Analysis of
fused images (SPET/CT) was done on a patient basis, with sep-
arated evaluation of SPET, low-dose CT images and fusion im-
ages. The gold standard for presence or absence of malignan-
cy was pathology or clinical and imaging follow-up data.
Results: SRS was negative in 6 patients and positive in 6.
SPET/CT provided no additional information in 6 patients, in-
cluding all 6 negative studies. SPET/CT improved localization
of SPET detected lesions in 6 positive studies. It defined the
extent of the disease and showed bone involvement in 3 of the
6 positive studies. SPET/CT affected the diagnostic interpre-
tation in 6 patients (50 %) and induced changes of manage-
ment in 3 (25 %).
Conclusion: The results of this study indicate that combined
anatomical-functional imaging with SPET/CT significantly im-
proves tumour localization and characterization, contributing to
a better therapeutic management of patients with NET.
KEY WORDS: Neuroendocrine tumours. Somatostatin
receptor scintigraphy. Image fusion. Anatomic-functional
imaging.
VALOR DE LA FUSIÓN DE IMÁGENES DE SPET/TAC EN
LA EVALUACIÓN DE TUMORES NEUROENDOCRINOS
CON GAMMAGRAFÍA CON 111IN-PENTATREÓTIDO
Resumen.—El objetivo de este estudio fue la evaluación
del impacto clínico de la imagen de fusión anatomo-funcional
en la interpretación gammagráfica y el manejo clínico de pa-
cientes con tumores neuroendocrinos (TNE), utilizando gam-
magrafía de receptores de la somatostatina (GRS) y tomogra-
fia de emisión-transmisión (SPET/TAC).
Material y método: 12 pacientes (8 mujeres y 4 hombres;
edad 32-74 años, media 56 años) con TNE diagnosticado o
clínicamente sospechado, fueron estudiados con GRS planar
y SPET/TAC a las 2 y 24 horas después de la inyección i.v. de
111-222 MBq de 111In-Pentatreótido. Siete pacientes fueron va-
lorados para estadificación/seguimiento y 5 pacientes para lo-
calización del tumor primario con estadificación. El análisis de
las imágenes de fusión (SPET/TAC) se realizó mediante la
evaluación de las imágenes de SPET, imágenes TAC de baja
dosis e imágenes de fusión. Como referencia para la presen-
cia o ausencia de malignidad se utilizan los datos de la histo-
patología o la evolución clínica.
Resultados: La GRS fue negativa en 6 pacientes y patoló-
gica en 6. SPET/TAC no aportó información adicional en los
6 pacientes GRS negativos. SPET/TAC facilitó la localización
de las lesiones detectadas con SPET en los estudios patoló-
gicos, aportó mayor información sobre la extensión de la en-
fermedad y mostró afectación ósea en 3 de los 6 estudios po-
sitivos. La SPET/TAC modificó la interpretación diagnostica
en 6 pacientes (50%) y ha inducido cambios en la decisión clí-
nica y terapéutica en 3 (25 %).
Conclusión: Los resultados de este trabajo inicial indican
que la combinación de las imágenes anatómico-funcionales
con SPET/TAC mejoran substancialmente la localización del
tumor y su caracterización, contribuyendo a un mejor manejo
clínico en pacientes con TNE.
PALABRAS CLAVE: Tumores neuroendocrinos. Gam-
magrafía de receptores de la somatostatina. Fusión de
imágenes. SPET/TAC.
INTRODUCTION
Neuroendocrine tumours (NET) are rare neo-
plasms corresponding to a very heterogeneous
group, which differ in histology, hormone produc-
tion and clinical behaviour1. Nuclear Medicine plays
an important role in the management of patients with
NET. The outcome of patients with NET is signifi-
cantly affected by accurate tumour localization and
precise determination of the extent of disease. Man-
agement of these patients is primarily based on sur-
gical removal of the primary lesion and single
originales
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metastases, as these slow growing tumours are only
minimally responsive to systemic chemotherapy. In
cases of evidence of multifocal metastatic spread,
the differentiated tumour may benefit from treat-
ment with therapeutic doses of cold or radiolabelled
ligand2. Recent studies indicate that somatostatin
receptor scintigraphy (SRS) is more sensitive than
sonography, CT, MRI and angiography, for identi-
fying these tumours and their metastases3,4. Howev-
er, the shortcomings of SRS in providing precise
anatomical localisation of lesions often necessitate
correlation with high-resolution anatomical imaging
modalities1,2.
SRS is a functional imaging modality based on
preferential binding of 111In-pentetreotide to somato-
statin receptors subtypes II and V4,6. It has the poten-
tial to define the extent of metastatic disease, to local-
ize the primary occult tumour site, and to identify
the receptor status of metastases for potential oc-
treotide treatment4,6. However, the detection of NET
remains challenging, due to their usually reduced di-
mensions and poorly defined anatomic localization.
Its specificity may also be affected by tracer uptake at
physiological sites or benign conditions. Because of
these limitations, SRS may benefit from co-registra-
tion with CT, with acquisition of nuclear medicine
and CT data during a single imaging session2-5. The
implementation of these SPET/CT imaging systems
has the advantages of minimizing the errors described
with co-registration of independently performed stud-
ies and optimizing anatomic localization of foci of in-
creased single photon emitting tracer uptake, in addi-
tion to a significant improvement in attenuation
correction.
The purpose of this study was to evaluate the con-
tribution of hybrid SPET/CT imaging to scintigraphic
evaluation, assessing as well fusion related changes
and the clinical impact in patients with NET.
MATERIAL AND METHODS
Twelve patients with proven or clinical suspicion
of NET were referred for SRS between February
2003 and January 2004. The patient population in-
cluded 8 females and 4 males, aged from 32 to
74 years (mean 57 ± 13 years).
Seven patients came for staging/follow-up and five
came for primary tumour localization with staging
(table I).
Scintigraphy was performed after i.v. administra-
tion of 111-222 MBq of 111In-Pentetreotide (Octre-
oscan, Mallinckrodt Medical). Planar views and
SPET/CT were obtained using a dual head, variable
angle gamma camera equipped with a medium ener-
gy collimator and a low-dose X-ray CT transmission
system, mounted on the same slip-ring gantry (Dis-
covery VH, with CoDe VC & Hawkeye options, GE
Medical Systems). The combined system that pro-
vides hybrid functional (SRS) and anatomic (low-
dose CT) images allows for acquisition of both pro-
cedures in the same setting, without changing the
patient’s positioning. Planar views were recorded for
15 minutes or up to 500 Kcts from skull to mid-thigh
at 2 h and 24 h after injection. SPET/CT of abdomen
and/or chest and/or pelvis was performed at 24 h after
injection.
For the CT component of the study, a cross-sec-
tional anatomic transmission map was acquired as the
system rotated around the patient, with a rotation
speed of 2,6 r.p.m.. Each slice acquisition, termed
“half-scan” was performed over 240°, taking 16 sec.
acquisition time for each transaxial slice. The x-ray
tube is operated at 140 KVp, 2,5 mA. Multiple slices
were obtained by moving the table by a slice step
(10 mm) before acquiring the next slice. The full
field-of-view, consisting of 40 slices, was completed
in 10 minutes. The transmission data were recon-
structed using filtered back-projection to produce
cross-sectional attenuation images in which each pix-
el represents the estimated attenuation of the imaged
tissue. Radiation exposure of the patient following a
transmission scan, calculated on the basis of phantom
studies, ranged from 1,3-3,5 mGy at the centre to
5 mGy at the surface (CTDIw = 3,54 mGy).
Following transmission, the emission part of the
study was acquired. Acquisition parameters included
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Primary tumour Staging Total
Tumour type
and staging follow-up
Pancreatic 2 3 5
Gastrointestinal carcinoid 1 3 4
Bronchopulmonary carcinoid 1 1 2
Metastatic NET (suspected) 1 – 1
Total 5 7 12
SRS: somatostatin receptor scintigraphy; NET: neuroendocrine tumour.
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a 360° rotation, 128 × 128 matrix, 6° angle step and
acquisition time of 45 sec. per frame for a total
33 min and 45 sec. per study. Reconstruction was per-
formed using the ordered subsets expectation maxi-
mization (OSEM) technique (2 iterations), to avoid
the artefacts seen with filtered back projection in ar-
eas adjacent to intense tracer activity. The resultant
emission images were inherently registered to the
anatomical maps. These matching pairs of X–ray and
nuclear medicine images were fused using the eNTE-
GRA workstation software (General Electric Medical
Systems) and images of overlying transmission (CT)
and emission (SPET) data were generated. Data ac-
quired during SPET/CT were used for anatomic lo-
calization of the scintigraphic findings.
SRS, including planar and SPET study were inter-
preted independently of SPET/CT images by a team
of nuclear medicine physicians. Subsequently, data
obtained from SPET/CT images analysis were com-
pared to the reports of SRS from the independent
analyses. SPET/CT data were confirmed with patho-
logical findings, when available, or with clinical and
radiological follow-up, during a 4 to 12 month peri-
od. SPET/CT was considered to improve image inter-
pretation once it provided a better localization of sites
of increased tracer uptake, or when it excluded dis-
ease in sites of physiological or benign tracer uptake.
Any change or adjustment in the patient manage-
ment, whether diagnostic or therapeutic, due to the
additional information provided by SPET/CT was
recorded.
RESULTS
Six patients had a negative SRS study, and six had
receptor-positive findings.
Among the 6 patients with negative SRS, no further
evidence of disease was documented. They included
1 patient with bronchopulmonary NET, 1 patient with
rectal NET (excised) and 2 patients with pancreatic
NET, who came for staging/follow-up. Two patients
with suspected carcinoid came for primary tumour
localization and staging. SPET/CT provided no added
value to image interpretation and to clinical decision
making in all 6 patients with negative SRS.
Among the 6 patients with positive SRS, disease
was confirmed pathologically in 2 patients (1 by
surgery and 1 by bronchoalveolar lavage analysis), ra-
diologically in 5 patients (CT or MRI) and by clinical
follow-up in one patient (suspected for insulinoma).
SPET/CT improved the image interpretation in all
6 SRS positive patients (100 % of patients with ab-
normal SRS, and 50 % of the whole group). Of these,
SPET/CT contributed to a better anatomic localiza-
tion in 3 patients, referred for detection of primary tu-
mour and 3 patients who came for staging/follow-up.
SPET/CT detected bronchopulmonary tracer uptake
(1 patient) and precisely confined tracer uptake in
pancreas (2 patients) of 3 patients referred for prima-
ry tumour detection. SPET/CT also identified unsus-
pected bone extension in 2 patients, during follow-up.
SPET/CT results affected patient management in
3 patients, 25 % of the total population and 50 % of
the cases where SPET/CT improved image interpre-
tation. It led to a surgical therapeutic approach with
chemotherapy in one patient with hepatic lesions in
whom was detected a primitive pancreatic NET
(fig. 1). In one patient, referred for follow-up after
surgery and chemotherapy, SRS-SPET/CT detected
bone metastases, which were no responsive to
chemotherapy, and was submitted to cold octreotide
first in mensal administrations, then weekly and fi-
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FIG. 1.—Patient with hepatic lesions and a primitive pancreatic NET
(marked). A) Low-dose CT images; B) SPET images; C) Fusion images.
A B C
MEDICINA NUCL v24 n1 2005  23/12/04  12:19  Página 16
nally in continued infusion due to worsening of
the general condition (fig. 2). This patient died at
4 months follow-up. In another patient with hepatic
lesions referred for primary tumour localization,
SPET/CT detected a bronchopulmonary carcinoid
(confirmed by bronchoalveolar lavage analysis). This
patient was considered not suitable for surgery and
was submitted to chemotherapy.
DISCUSSION
Somatostatin receptors are present on almost all
neuroendocrine cells. As a consequence, 111In-Pente-
treotide scintigraphy has shown a high sensitivity for
the diagnosis of both primary and metastatic tumour
lesions6,7. Although peptide receptor scintigraphy
may be useful as a tumour localizing technique in a
variety of diseases where it may detect tumour local-
izations prior to or in addition to conventional imag-
ing, it will never be competitive with, for instance,
CT or MRI in anatomic delineation of these disease
sites8. The incidence of multiple organ involvement in
patients with NET is high. The knowledge of the pre-
cise extent of disease plays a major role in determin-
ing the appropriate treatment option and choice of
treatment procedures such as chemotherapy, cytore-
ductive surgery, embolization, or liver transplanta-
tion3. Diagnosis of bone metastasis is of prognostic
significance, indicating short survival and patients
may also be spared unnecessary surgery.
In the present study, fusion of functional and
anatomic images obtained sequentially on the same
imaging device showed an additional value in the di-
agnostic capacities of SRS-SPET and CT. SPET/CT
improved SRS image interpretation in 6 of the
12 study group patients (50 %), not only due to a
more accurate localization of tumour sites but also
due to the x-ray based attenuation correction, which
results in improved image quality for SPET images.
Among these 12 patients, 6 patients were referred
for detection of primary tumour and staging and 6 pa-
tients were evaluated for extent of disease and for fol-
low-up. The primary tumour was detected in 3 pa-
tients (2 pancreatic NET and 1 bronchopulmonary
carcinoid) and bone involvement in 3. SRS-SPET/CT
guided the therapeutic approach in 3 cases (25 %).
The results of our study, evaluating combined
SPET/CT in patients with NET are in agreement with
the published data.
CONCLUSION
The results of this study indicate that the introduc-
tion of dual-head gamma camera with an integrated
x-ray transmission system (low dose CT) for attenu-
ation correction, anatomical mapping and image fu-
sion, improves image interpretation and provides cor-
rect anatomic localization of SRS findings in patients
with NET. Hybrid imaging is an accurate, simply
achieved method of registration of functional and
anatomic data which enhances the already unique
role of SRS in the assessment of these tumours. It im-
proves guidance of invasive diagnostic and therapeu-
tic procedures and may help in monitoring therapeu-
tic outcomes.
REFERENCES
1. Pfannenberg AC, Eschmann SM, Horger M, Lamberts R, Von-
thein R, Claussen CD, et al. Benefit of anatomical-functional im-
age fusion in the diagnostic work-up of neuroendocrine neo-
plasms. Eur J Nucl Med Mol Imaging 2003;30:835-43.
Paula Moreira A, et al. Value of SPET/CT Image Fusion in the Assessment of Neuroendocrine Tumours with 111In-Pentetreotide Scintigraphy
31 17Rev Esp Med Nucl, 2005;24(1):14-8
FIG. 2.—SRS-SPET/CT detected new bone metastases, in a patient
who was no responsive to chemotherapy, and was submitted to cold
octreotide. A lesion in the right femur is shown. A) Low-dose CT ima-
ges; B) SPET images; C) Fusion images.
A B C
MEDICINA NUCL v24 n1 2005  23/12/04  12:19  Página 17
2. Krausz Y, Keidar Z, Kogan I, Even-Sapir E, Shalom RB, Engel A, et
al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment
of Neuroendocrine tumours. Clin Endocrinol 2003;59:565-73.
3. Even-Sapir E, Keidar Z, Sachs J, Engel A, Bettman L, Gaitini D,
et al.The New Technology of Combined Transmission and Emis-
sion Tomography in Evaluation of Endocrine Neoplasms. J Nucl
Med 2001;42:998-1004.
4. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP,
Kooij PPM, Oei HY, et al. Somatostatin receptor scintigraphy
with 111In-DTPA-D-Phe1- and 123I-Tyr3-octreotide: the Rotter-
dam experience with more than 1000 patients. Eur J Nucl Med
1993;20:716-31.
5. Patton JA, Delbeke D, and Sandler MP. Image Fusion Using an
Integrated, Dual-Head Coincidence Camera with X-ray Tube-
Based Attenuation Maps. J Nucl Med 2000;41:1364-8.
6. Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neu-
roendocrine tumours: biological basis and diagnostic results. Eur
J Nucl Med 1998;25:639-58.
7. Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, et
al. Comparison of somatostatin receptor imaging, computed to-
mography and ultrasound in the clinical management of neuroen-
docrine gastro-entero-pancreatic tumours. Eur J Nucl Med
1998;25:1396-403.
8. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC.
Somatostatin Receptor Scintigraphy. En: Freeman LM, editor.
Nuclear Medicine Annual 1995. New York: Raven Press, 1995;
p. 1-50.
9. Keidar Z, Israel O, Krausz Y. SPECT/CT in Tumor Imaging:
Technical Aspects and Clinical Applications. Semin Nucl Med
2003;33:205-18.
Paula Moreira A, et al. Value of SPET/CT Image Fusion in the Assessment of Neuroendocrine Tumours with 111In-Pentetreotide Scintigraphy
3218 Rev Esp Med Nucl, 2005;24(1):14-8
MEDICINA NUCL v24 n1 2005  23/12/04  12:19  Página 18
